Shots:
- Infinimmune has partnered with Merck to discover & develop antibody candidates against multiple undisclosed targets selected by Merck using Infinimmune’s human-first antibody discovery platform
- As per the deal, Infinimmune will use its Anthrobody discovery platform & Glimpse antibody language model to discover & optimize antibodies from human immune repertoires, enabling large-scale B-cell screening to identify high-affinity, specific candidates with favorable drug-like properties
- Merck will obtain exclusive rights to develop & commercialize antibodies from the collaboration, while Infinimmune will receive an undisclosed upfront payment & is eligible for milestone payments all totaling up to $838M
Ref: Businesswire | Image: Merck & Infinimmune | Press Release
Related News: Merck to Acquire Terns Pharmaceuticals for ~$6.7B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
